Affinium initiates dosing in Stage 1 IV clinical trial of antibiotic prodrug.

‘Normally occurs in intervals of hysteria, these long term citizens are accepting the fundamentally illiberal message that convicting the innocent is a price to pay to achieve the greater good.’.. Affinium initiates dosing in Stage 1 IV clinical trial of antibiotic prodrug, AFN-1720 Affinium Pharmaceuticals announced today that it has initiated dosing in a Phase 1 intravenous clinical trial of its new antibiotic prodrug, AFN-1720. AFN-1720 may be the prodrug of the energetic drug, AFN-1252. Initiation of this IV clinical study comes after Affinium's 2012 successful oral Phase 2a clinical research demonstrating excellent protection, efficacy and tolerability in acute bacterial pores and skin and skin structure attacks .Cancer cells may be distinguished from normal cells by their elevated levels of sugar on the cell surface area. The mAbs uncovered and produced by BTI have the ability to recognise these sugar targets and allow more accurate identification of cancers cells in comparison with traditional antibodies that only target proteins. MAbs generated by BTI are also exclusive in having a novel system of action; they cause pores to form on the top of cancer cells, leading to cell degradation and the eventual death of these diseased cells.